Q2 EPS Estimate for Niagen Bioscience Increased by Analyst

Key Points

• Roth Capital raised its Q2 2026 EPS estimate for Niagen Bioscience to $0.04 per share, up from a previous forecast of $0.01, maintaining a "Buy" rating with a price target of $23.00.
• Niagen Bioscience reported Q2 earnings of $0.04 per share, exceeding the consensus estimate of $0.02, alongside a revenue of $31.12 million, surpassing expectations.
• Various brokerages have recently upgraded or adjusted their ratings on Niagen Bioscience, with the stock currently holding a consensus "Buy" rating and a price target around $13.22.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Stock analysts at Roth Capital lifted their Q2 2026 EPS estimates for shares of Niagen Bioscience in a report issued on Thursday, August 7th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings of $0.04 per share for the quarter, up from their prior estimate of $0.01. Roth Capital currently has a "Buy" rating and a $23.00 target price on the stock.

A number of other brokerages have also weighed in on NAGE. Canaccord Genuity Group boosted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. HC Wainwright upped their price target on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a "buy" rating in a report on Monday. Finally, Wall Street Zen lowered shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 2nd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Niagen Bioscience has an average rating of "Buy" and a consensus target price of $13.42.

Niagen Bioscience Trading Up 1.8%

Shares of NAGE traded up $0.17 during mid-day trading on Monday, reaching $9.88. The company's stock had a trading volume of 323,185 shares, compared to its average volume of 947,641. The stock has a market cap of $787.93 million, a PE ratio of 47.05 and a beta of 2.12. Niagen Bioscience has a 52 week low of $3.10 and a 52 week high of $14.69. The company's fifty day moving average price is $11.63 and its two-hundred day moving average price is $8.41.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The firm had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

Institutional Investors Weigh In On Niagen Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new stake in Niagen Bioscience during the 4th quarter valued at $555,000. Two Sigma Investments LP purchased a new position in Niagen Bioscience during the 4th quarter valued at $675,000. State of Wyoming purchased a new position in Niagen Bioscience during the 4th quarter valued at $39,000. Sherbrooke Park Advisers LLC purchased a new position in Niagen Bioscience during the 4th quarter valued at $94,000. Finally, ProShare Advisors LLC purchased a new position in Niagen Bioscience during the 4th quarter valued at $74,000. 15.41% of the stock is currently owned by institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.